Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 17/20 | 0.78 |
| ▸ | CDK4 | P11802 | 14/20 | 0.78 |
| ▸ | CDK6 | Q00534 | 10/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515005 | 0.88 | CCND1 (1.00) | CCND1CDK4CDK6CDK1CDK2 | |
| SCHEMBL25235418 | 0.81 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL29515081 | 0.81 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL29515132 | 0.81 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL25285212 | 0.81 | CCND1 (0.79) | CCND1CDK4CDK6 | |
| SCHEMBL29514918 | 0.81 | CCND1 (0.84) | CCND1CDK4CDK6CDK2CDK7 | |
| SCHEMBL24322347 | 0.81 | CCND1 (0.84) | CCND1CDK4CDK6CDK2CDK7 | |
| SCHEMBL29514949 | 0.81 | CCND1 (0.78) | CCND1CDK4CDK6 | |
| SCHEMBL24322101 | 0.80 | CCND1 (1.00) | CCND1CDK4CDK6 | |
| SCHEMBL25237805 | 0.79 | CCND1 (1.00) | CCND1CDK4CDK6CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | claimed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | claimed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.